青蒿
青蒿素
转基因
倍半萜内酯
转化(遗传学)
转基因作物
生物
基因
植物
倍半萜
生物化学
恶性疟原虫
疟疾
免疫学
作者
Ya-Xiong Wang,Shiping Long,Lixia Zeng,Lien Xiang,Zhi Lin,Min Chen,Zhihua Liao
出处
期刊:Acta pharmaceutica Sinica
日期:2014-09-01
卷期号:49 (9): 1346-1352
被引量:2
摘要
Artemisnin is a novel sesquiterpene lactone with an internal peroxide bridge structure, which is extracted from traditional Chinese herb Artemisia annua L. (Qinghao). Recommended by World Health Organization, artemisinin is the first-line drug in the treatment of encephalic and chloroquine-resistant malaria. In the present study, transgenic A. annua plants were developed by overexpressing the key enzymes involved in the biosynthetic pathway of artemisinin. Based on Agrobacterium-mediated transformation methods, transgenic plants of A. annua with overexpression of both HDR and ADS were obtained through hygromycin screening. The genomic PCR analysis confirmed six transgenic lines in which both HDR and ADS were integrated into genome. The gene expression analysis given by real-time quantitative PCR showed that all the transgenic lines had higher expression levels of HDR and ADS than the non-transgenic control (except ah3 in which the expression level of ADS showed no significant difference compared with control); and the HPLC analysis of artemisinin demonstrated that transgenic A. annua plants produced artemisinin at significantly higher level than non-transgenic plants. Especially, the highest content of artemisinin was found in transgenic line ah70, in which the artemisinin content was 3.48 times compared with that in non-transgenic lines. In summary, overexpression of HDR and ADS facilitated artemisinin biosynthesis and this method could be applied to develop transgenic plants of A. annua with higher yield of artemisinin.
科研通智能强力驱动
Strongly Powered by AbleSci AI